高危前列腺癌根治性治疗后的疾病轨迹:一项基于人群的研究
基于瑞典前列腺癌数据库5.0,纳入2006-2020年诊断的高危局限性或局部晚期前列腺癌男性,接受根治性放疗或根治性前列腺切除术,随访至2021年6月30日。共8317例接受放疗、4923例接受手术,中位随访6.2年,采用竞争风险分析评估治疗轨迹及前列腺癌死亡风险。
要点
- 放疗后10年前列腺癌死亡风险为0.13(95%CI 0.12-0.14),全因死亡风险为0.32(95%CI 0.31-0.34)。
- 手术后10年前列腺癌死亡风险为0.09(95%CI 0.08-0.10),全因死亡风险为0.19(95%CI 0.18-0.21)。
- 接受二级雄激素剥夺治疗者,自开始ADT起10年前列腺癌死亡风险放疗后为0.33(95%CI 0.30-0.36),手术后为0.27(95%CI 0.24-0.30)。
核心结论
- 接受根治性放疗或根治性前列腺切除术的高危前列腺癌男性中,约十分之一在诊断后10年死于前列腺癌。
- 接受二级雄激素剥夺治疗(提示前列腺癌进展)的男性中,约三分之一在开始ADT后10年死于前列腺癌。
- 作者认为,早期识别并积极治疗根治性治疗后高进展风险男性是有必要的。
研究设计与样本
- 基于人群的队列研究,数据来自瑞典前列腺癌数据库(PCBaSe)5.0。
- 纳入2006-2020年诊断的高危局限性或局部晚期前列腺癌男性,接受原发性根治性放疗或根治性前列腺切除术,随访至2021年6月30日。
- 共8317例接受根治性放疗,4923例接受根治性前列腺切除术。
- 采用竞争风险分析,以累积发生率评估各事件风险。
主要发现
- 中位随访6.2年(四分位距3.6-9.5年)。
- 放疗后10年前列腺癌死亡风险为0.13(95%CI 0.12-0.14),全因死亡风险为0.32(95%CI 0.31-0.34)。
- 手术后10年前列腺癌死亡风险为0.09(95%CI 0.08-0.10),全因死亡风险为0.19(95%CI 0.18-0.21)。
- 放疗后10年二级ADT风险为0.42(95%CI 0.41-0.44),手术后为0.21(95%CI 0.20-0.23)。
- 接受二级ADT者中,自开始ADT起10年前列腺癌死亡风险放疗后为0.33(95%CI 0.30-0.36),手术后为0.27(95%CI 0.24-0.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate long-term disease trajectories among men with high-risk localized or locally advanced prostate cancer (HRLPC) treated with radical radiotherapy (RT) or radical prostatectomy (RP). MATERIAL AND METHODS: Men diagnosed with HRLPC in 2006-2020, who received primary RT or RP, were identified from the Prostate Cancer data Base Sweden (PCBaSe) 5.0. Follow-up ended on 30 June 2021. Treatment trajectories and risk of death from prostate cancer (PCa) or other causes were assessed by competing risk analyses using cumulative incidence for each event. RESULTS: In total, 8317 men received RT and 4923 men underwent RP. The median (interquartile range) follow-up was 6.2 (3.6-9.5) years. After RT, the 10-year risk of PCa-related death was 0.13 (95% confidence interval [CI] 0.12-0.14) and the risk of death from all causes was 0.32 (95% CI 0.31-0.34). After RP, the 10-year risk of PCa-related death was 0.09 (95% CI 0.08-0.10) and the risk of death from all causes was 0.19 (95% CI 0.18-0.21). The 10-year risks of androgen deprivation therapy (ADT) as secondary treatment were 0.42 (95% CI 0.41-0.44) and 0.21 (95% CI 0.20-0.23) after RT and RP, respectively. Among men who received ADT as secondary treatment, the risk of PCa-related death at 10 years after initiation of ADT was 0.33 (95% CI 030-0.36) after RT and 0.27 (95% CI 0.24-0.30) after RP. CONCLUSION: Approximately one in 10 men with HRLPC who received primary RT or RP had died from PCa 10 years after diagnosis. Approximately one in three men who received secondary ADT, an indication of PCa progression, died from PCa 10 years after the start of ADT. Early identification and aggressive treatment of men with high risk of progression after radical treatment are warranted.
引用
- Stattin P, Fleming S, Lin X, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024. PMID: 38621388. doi:10.1111/bju.16362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。